Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation

por Cardona‐Gonzalez, Maria G., Goldman, Jason D., Narayan, Lawrence, Brainard, Diana M., Kowdley, Kris V.
Publicado 2018

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline

por Campbell, Thomas, Clarke, Amanda, Trottier, Benoit, Carter, Christoph C, Shao, Yongwu, Ebrahimi, Ramin, Das, Moupali, Brainard, Diana M, Gladstein, Jay
Publicado 2020

476. Gilead Sciences’ Commitment to the COVID-19 Pandemic

por Lee, EunYoung, Osinusi, Anu, Chokkalingam, Anand, Brainard, Diana M, Tran, Tram, Dau, Lauren, Ferrinho, Diogo, Wang, ChenYu, Juneja, Kavita
Publicado 2020

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

por Lawitz, Eric, Poordad, Fred, Brainard, Diana M, Hyland, Robert H, An, Di, Dvory-Sobol, Hadas, Symonds, William T, McHutchison, John G, Membreno, Fernando E
Publicado 2015

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes

por Chaturvedi, Nimisha, Svarovskaia, Evguenia S, Mo, Hongmei, Osinusi, Anu O, Brainard, Diana M, Subramanian, G Mani, McHutchison, John G, Zeuzem, Stefan, Fellay, Jacques
Publicado 2019

985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial

por Daar, Eric, Brunetta, Jason, Cua, Eric, Flamm, Jason, Asmuth, David, Carter, Christoph C, Shao, Yongwu, Wong, Pamela, Ebrahimi, Ramin, Das, Moupali, Brainard, Diana M, Clarke, Amanda
Publicado 2020

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study

por Ruane, Peter, Strasser, Simone I., Gane, Edward J., Hyland, Robert H., Shao, Jiang, Dvory‐Sobol, Hadas, Tran, Tram, Stamm, Luisa M., Brainard, Diana M., Nyberg, Lisa, Shafran, Stephen
Publicado 2019

Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis

por Uchida, Yoshihito, Nakamura, Shugo, Kouyama, Jun-Ichi, Naiki, Kayoko, Motoya, Daisuke, Sugawara, Kayoko, Inao, Mie, Imai, Yukinori, Nakayama, Nobuaki, Tomiya, Tomoaki, Hedskog, Charlotte, Brainard, Diana, Mo, Hongmei, Mochida, Satoshi
Publicado 2018

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

por Sax, Paul E, Rockstroh, Jürgen K, Luetkemeyer, Anne F, Yazdanpanah, Yazdan, Ward, Douglas, Trottier, Benoit, Rieger, Armin, Liu, Hui, Acosta, Rima, Collins, Sean E, Brainard, Diana M, Martin, Hal
Publicado 2020

Lack of Detectable HIV-1–Specific CD8(+) T Cell Responses in Zambian HIV-1–Exposed Seronegative Partners of HIV-1–Positive Individuals

por Addo, Marylyn M., Altfeld, Marcus, Brainard, Diana M., Rathod, Almas, Piechocka-Trocha, Alicja, Fideli, Ulgen, Mulenga, Joseph, Shutes, Erin, Alvino, Donna Marie L., Hunter, Eric, Allen, Susan A., Walker, Bruce D.
Publicado 2011

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial

por Mills, Anthony, Workowski, Kimberly, Campbell, Thomas, Benson, Paul, Crofoot, Gordon, Salazar, Laura, Ogbuagu, Onyema, Shalit, Peter, Trottier, Benoit, Carter, Christoph C, Wong, Pamela, Brainard, Diana M, McCallister, Scott, Das, Moupali, Doblecki-Lewis, Susanne
Publicado 2019

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial

por Wohl, David, Ruane, Peter, Hosek, Sybil, Creticos, Catherine, Morris, Sheldon, Phoenix, John, Ramgopal, Moti, Brinson, Cynthia, Tremblay, Cecile, Carter, Christoph C, Wong, Pamela, Brainard, Diana M, McCallister, Scott, Das, Moupali, Thompson, Melanie A
Publicado 2019

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

por Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K, Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn, Ramgopal, Moti, McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E, Brainard, Diana M, Martin, Hal
Publicado 2020

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

por Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K., Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn O., Ramgopal, Moti N., McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E., Brainard, Diana M., Martin, Hal
Publicado 2021

Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials

por Orkin, Chloe, Ajana, Faiza, Kityo, Cissy, Koenig, Ellen, Natukunda, Eva, Gandhi-Patel, Bhumi, Wang, Hui, Liu, Yapei, Wei, Xuelian, White, Kirsten, Makadzange, Tariro, Pikora, Cheryl, McNicholl, Ian, Collins, Sean E., Brainard, Diana, Chuck, Susan K.
Publicado 2021

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Diseas...

por Eron, Joseph J, Wilkin, Aimee, Ramgopal, Moti, Osiyemi, Olayemi, McKellar, Mehri, McKellar, Mehri, Slim, Jihad, Asmuth, David, DeJesus, Edwin, German, Polina, Blair, Christiana, Carter, Christoph C, Brainard, Diana M, Collins, Sean E, Martin, Hal
Publicado 2020

The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment

por Gane, Edward J., Metivier, Sophie, Nahass, Ronald, Ryan, Michael, Stedman, Catherine A., Svarovskaia, Evguenia S., Mo, Hongmei, Doehle, Brian, Dvory‐Sobol, Hadas, Hedskog, Charlotte, Lin, Ming, Brainard, Diana M., Yang, Jenny C., McHutchison, John G., Sulkowski, Mark, Younes, Ziad, Lawitz, Eric
Publicado 2017

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

por Shiha, Gamal, Esmat, Gamal, Hassany, Mohamed, Soliman, Reham, Elbasiony, Mohamed, Fouad, Rabab, Elsharkawy, Aisha, Hammad, Radi, Abdel-Razek, Wael, Zakareya, Talaat, Kersey, Kathryn, Massetto, Benedetta, Osinusi, Anu, Lu, Sophia, Brainard, Diana M, McHutchison, John G, Waked, Imam, Doss, Wahid
Publicado 2019

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

por Schwarz, Kathleen B., Rosenthal, Philip, Murray, Karen F., Honegger, Jonathan R., Hardikar, Winita, Hague, Rosie, Mittal, Naveen, Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Narkewicz, Michael R., Rao, Girish S., Whitworth, Suzanne, Bansal, Sanjay, Balistreri, William F.
Publicado 2019

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies

por Grebely, Jason, Feld, Jordan J, Wyles, David, Sulkowski, Mark, Ni, Liyun, Llewellyn, Joe, Mir, Heshaam M, Sajed, Nika, Stamm, Luisa M, Hyland, Robert H, McNally, John, Brainard, Diana M, Jacobson, Ira, Zeuzem, Stefan, Bourlière, Marc, Foster, Graham, Afdhal, Nezam, Dore, Gregory J
Publicado 2018